Medicine

The first CRISPR gene-editing medicine is approved for sickle cell disease

Casgevy edits a patient's own blood stem cells so their body makes healthy foetal haemoglobin again.

Share on X WhatsApp Facebook

In 30 seconds

  • Casgevy, from Vertex and CRISPR Therapeutics, was approved in the UK in November 2023 and the US in December 2023.
  • It is the first approved medicine that uses CRISPR gene editing.
  • It treats sickle cell disease, and later beta thalassaemia, with a one-time treatment.

In late 2023, medicine regulators in the United Kingdom and then the United States approved Casgevy, the first treatment to use CRISPR, the gene-editing tool whose inventors won the 2020 Nobel Prize in Chemistry.

How the treatment works

Doctors collect the patient’s blood stem cells. In a lab, CRISPR is used to switch off a gene called BCL11A. That gene normally stops the body from making foetal haemoglobin after birth. With it switched off, the edited cells make foetal haemoglobin again, which does not form the sickle shapes that block blood vessels.

The patient receives chemotherapy to clear space in the bone marrow, and the edited cells are then put back.

The results

In the clinical trial, most patients with severe sickle cell disease stopped having the painful crises that put them in hospital for at least a year.

The catch

The treatment is complex and very expensive, and it needs specialist hospitals. Long-term effects of the edits are still being studied.

Why it matters for India

India has one of the world's largest populations living with sickle cell disease, especially in tribal communities, and the government has launched a national mission to eliminate it. Indian scientists are now developing lower-cost gene therapies for the same conditions.

Our take

This is a cure-level result for many patients, but the price is in the millions of dollars and the treatment needs chemotherapy and a long hospital stay. Making it affordable and practical is the next big challenge, and it is one where Indian research could lead.

Sources

We read these before writing this story. Go to them for the full detail.

  1. US Food and Drug Administration
  • CRISPR
  • gene therapy
  • sickle cell
  • Vertex

Type to search every story. Use the arrow keys and Enter to open one.